• 1. Breast Disease Center of West China Hospital, Sichuan University, Chengdu, 610041, P. R. China;
  • 2. Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P. R. China;
  • 3. Department of Oncologic Plastic Surgery, Hunan Cancer Hospital, Changsha, 410013, P. R. China;
  • 4. Department of Breast Surgery, Beijing Chao-yang Hospital, Capital Medical University, Beijing, 100020, P. R. China;
  • 5. Breast Surgery Department, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China;
DU Zhenggui, Email: docduzg@163.com
Export PDF Favorites Scan Get Citation

Recent research from the International Agency for Research on Cancer (IARC) of the World Health Organization (WHO) indicates that breast cancer is the most prevalent malignant tumor among women, posing a significant threat to women's health. Surgery remains the primary therapeutic modality for breast cancer. Recently, endoscopic and robotic breast surgical techniques have gained acceptance among both surgeons and patients. However, considerable variation exists in surgical approaches and outcomes. To standardize these techniques, facilitate their broader clinical adoption, and ultimately improve patient care, the Endoscopic-robotic Breast Surgery Clinical Trials Consortium (ErBSCTC) of the China National Health Association (CNHA) has developed this guideline and consensus statement. This document encompasses the technologies and instrumentation utilized in endoscopic and robotic breast surgery, surgical techniques, perioperative management, complication handling, long-term follow-up, and oncologic outcomes, aiming to provide evidence-based guidance for healthcare professionals involved in the prevention, diagnosis, and treatment of breast diseases.

Copyright ? the editorial department of Chinese Journal of Clinical Thoracic and Cardiovascular Surgery of West China Medical Publisher. All rights reserved